Which is NOT a significant side effect of doxorubicin?

Doxorubicin, an anthracycline antibiotic used in chemotherapy, is associated with several significant side effects due to its mechanism of action and physiological impacts. Among these, cardiotoxicity is well-documented and is one of the most concerning long-term effects, as it can lead to heart failure. Nausea and vomiting are common side effects of many chemotherapeutic agents, including doxorubicin, due to its effects on the gastrointestinal lining and the central nervous system.

Severe myelosuppression refers to the suppression of bone marrow activity, leading to decreased production of blood cells, which can cause anemia, increased risk of infections, and bleeding. While doxorubicin does have some degree of myelosuppressive effects, it is generally less severe compared to other chemotherapeutic agents, especially when viewed in the context of various treatments.

Hyperglycemia, on the other hand, is not a typical side effect of doxorubicin. This drug does not directly impact blood sugar levels the way steroids or certain other medications might. Therefore, recognizing that hyperglycemia is not a significant concern related to the use of doxorubicin helps clarify why this option stands out among the others as the one that is not commonly